The hallmarks of cancer: A long non-coding RNA point of view

RNA Biology

Volumn 9, Issue 6, 2012, Pages 703-719

  Gutschner, Tony ^a,b   Diederichs, Sven ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cancer therapy; Carcinogenesis; Gene expression; HOTAIR; lincRNA; MALAT1; ncRNA; Non coding RNA; T UCR; Tumor biology; XIST

Indexed keywords

ANDROGEN RECEPTOR; ANTISENSE NON CODING RNA IN THE INK4 LOCUS; CASPASE 3; CASPASE 8; CISPLATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTROGEN RECEPTOR; ETOPOSIDE; GLUCOCORTICOID RECEPTOR; GROWTH ARREST SPECIFIC PROTEIN 5; HETEROGENOUS RIBONUCLEOPROTEIN; HIGH MOBILITY GROUP A1A PROTEIN; METASTASIS ASSOCIATED LONG ADENOCARCINOMA TRANSCRIPT 1; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; RANPIRNASE; RAPAMYCIN; REPLICATION FACTOR A; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERIC REPEAT CONTAINING RNA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNTRANSLATED RNA; UVOMORULIN; VASCULOTROPIN A;

ANGIOGENESIS; APOPTOSIS; AUTOPHAGY; BINDING SITE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL DEATH; CELL DIFFERENTIATION; CELL DIVISION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; COLON CANCER; COLORECTAL CANCER; CYTOPLASM; DISTANT METASTASIS; DNA DAMAGE; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENE THERAPY; HEMATOPOIETIC STEM CELL; HUMAN; LIVER CANCER; LOSS OF FUNCTION MUTATION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MITOSIS; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN RNA BINDING; REVIEW; RNA ANALYSIS; RNA INTERFERENCE; RNA PURIFICATION; RNA REPLICATION; RNA STABILITY; SUMOYLATION; TELOMERE; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; UPREGULATION; UTERINE CERVIX CANCER;

EID: 84863495094     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.4161/rna.20481     Document Type: Review

References (210)

1. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al.; International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001; 409:860-921; PMID:11237011; http://dx.doi.org/10.1038/35057062.
2. Bertone P, Stolc V, Royce TE, Rozowsky JS, Urban AE, Zhu X, et al. Global identification of human transcribed sequences with genome tiling arrays. Science 2004; 306:2242-6; PMID:15539566; http://dx.doi.org/10.1126/science. 1103388.
3. Birney E, Stamatoyannopoulos JA, Dutta A, Guigó R, Gingeras TR, Margulies EH, et al.; ENCODE Project Consortium; NISC Comparative Sequencing Program; Baylor College of Medicine Human Genome Sequencing Center; Washington University Genome Sequencing Center; Broad Institute; Children's Hospital Oakland Research Institute. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 2007; 447:799-816; PMID:17571346; http://dx.doi.org/10.1038/nature05874.
4. Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, et al.; FANTOM Consortium; RIKEN Genome Exploration Research Group and Genome Science Group (Genome Network Project Core Group). The transcriptional landscape of the mammalian genome. Science 2005; 309:1559-63; PMID:16141072; http://dx.doi.org/ 10.1126/science.1112014.
5. Cheng J, Kapranov P, Drenkow J, Dike S, Brubaker S, Patel S, et al. Transcriptional maps of 10 human chromosomes at 5-nucleotide resolution. Science 2005; 308:1149-54; PMID:15790807; http://dx.doi.org/10.1126/science.1108625.
6. Kapranov P, Cheng J, Dike S, Nix DA, Duttagupta R, Willingham AT, et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science 2007; 316:1484-8; PMID:17510325; http://dx.doi.org/10. 1126/science.1138341.
7. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6:857-66; PMID:17060945; http://dx.doi.org/10.1038/nrc1997.
8. Trang P, Weidhaas JB, Slack FJ. MicroRNAs as potential cancer therapeutics. Oncogene 2008; 27:52-7; PMID:19956180; http://dx.doi.org/10.1038/ onc.2009.353.
9. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009; 11:228-34; PMID:19255566; http://dx.doi.org/10.1038/ncb0309-228.
10. Chen LL, Carmichael GG. Long noncoding RNAs in mammalian cells: what, where and why? Wiley Interdiscip Rev RNA 2010; 1:2-21; PMID:21956903.
11. Lipovich L, Johnson R, Lin CY. MacroRNA underdogs in a microRNA world: evolutionary, regulatory and biomedical significance of mammalian long non-protein-coding RNA. Biochim Biophys Acta 2010; 1799:597-615; PMID:20951849.
12. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell 2009; 136:629-41; PMID:19239885; http://dx.doi.org/10.1016/j.cell. 2009.02.006.
13. Dinger ME, Pang KC, Mercer TR, Mattick JS. Differentiating protein-coding and noncoding RNA: challenges and ambiguities. PLoS Comput Biol 2008; 4:1000176; PMID:19043537; http://dx.doi.org/10.1371/journal.pcbi.1000176.
14. Okazaki Y, Furuno M, Kasukawa T, Adachi J, Bono H, Kondo S, et al.; FANTOM Consortium; RIKEN Genome Exploration Research Group Phase I & II Team. Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature 2002; 420:563-73; PMID:12466851; http://dx.doi.org/10.1038/nature01266.
15. Kapranov P, Drenkow J, Cheng J, Long J, Helt G, Dike S, et al. Examples of the complex architecture of the human transcriptome revealed by RACE and high-density tiling arrays. Genome Res 2005; 15:987-97; PMID:15998911; http://dx.doi.org/10.1101/gr.3455305.
16. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet 2009; 10:155-9; PMID:19188922; http://dx.doi.org/10. 1038/nrg2521.
17. Gibb EA, Vucic EA, Enfield KS, Stewart GL, Lonergan KM, Kennett JY, et al. Human cancer long non-coding RNA transcriptomes. PLoS One 2011; 6:25915; PMID:21991387; http://dx.doi.org/10.1371/journal.pone.0025915.
18. Hutzinger R, Mrázek J, Vorwerk S, Hüttenhofer A. NcRNA-microchip analysis: a novel approach to identify differential expression of noncoding RNAs. RNA Biol 2010; 7:586-95; PMID:21037422; http://dx.doi.org/10. 4161/rna.7.5.12971.
19. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA 2009; 106:11667-72; PMID:19571010; http://dx.doi.org/10.1073/pnas.0904715106.
20. Loewer S, Cabili MN, Guttman M, Loh YH, Thomas K, Park IH, et al. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet 2010; 42:1113-7; PMID:21057500; http://dx.doi.org/10.1038/ng.710.
21. Peng X, Gralinski L, Armour CD, Ferris MT, Thomas MJ, Proll S, et al. Unique signatures of long non-coding RNA expression in response to virus infection and altered innate immune signaling. MBio 2010; 1; PMID:20978541; http://dx.doi.org/10.1128/mBio.00206-10.
22. Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 2011; 29:742-9; PMID:21804560; http://dx.doi.org/10.1038/nbt.1914.
23. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007; 129:1311-23; PMID:17604720; http://dx.doi.org/10. 1016/j.cell.2007.05.022.
24. Wang KC, Yang YW, Liu B, Sanyal A, Corces-Zimmerman R, Chen Y, et al. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature 2011; 472:120-4; PMID:21423168; http://dx.doi.org/10.1038/ nature09819.
25. Jia H, Osak M, Bogu GK, Stanton LW, Johnson R, Lipovich L. Genome-wide computational identification and manual annotation of human long noncoding RNA genes. RNA 2010; 16:1478-87; PMID:20587619; http://dx.doi.org/10.1261/rna. 1951310.
26. Chodroff RA, Goodstadt L, Sirey TM, Oliver PL, Davies KE, Green ED, et al. Long noncoding RNA genes: conservation of sequence and brain expression among diverse amniotes. Genome Biol 2010; 11:72; PMID:20624288; http://dx.doi.org/10.1186/gb-2010-11-7-r72.
27. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 2009; 458:223-7; PMID:19182780; http://dx.doi.org/10. 1038/nature07672.
28. Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 2010; 142:409-19; PMID:20673990; http://dx.doi.org/10.1016/j.cell.2010.06.040.
29. Hutchinson JN, Ensminger AW, Clemson CM, Lynch CR, Lawrence JB, Chess A. A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 splicing domains. BMC Genomics 2007; 8:39; PMID:17270048; http://dx.doi.org/10.1186/1471-2164-8-39.
30. Bejerano G, Pheasant M, Makunin I, Stephen S, Kent WJ, Mattick JS, et al. Ultraconserved elements in the human genome. Science 2004; 304:1321-5; PMID:15131266; http://dx.doi.org/10.1126/science.1098119.
31. Calin GA, Liu CG, Ferracin M, Hyslop T, Spizzo R, Sevignani C, et al. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell 2007; 12:215-29; PMID:17785203; http://dx.doi.org/10. 1016/j.ccr.2007.07.027.
32. Amaral PP, Neyt C, Wilkins SJ, Askarian-Amiri ME, Sunkin SM, Perkins AC, et al. Complex architecture and regulated expression of the Sox2ot locus during vertebrate development. RNA 2009; 15:2013-27; PMID:19767420; http://dx.doi.org/10.1261/rna.1705309.
33. Fu X, Ravindranath L, Tran N, Petrovics G, Srivastava S. Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1. DNA Cell Biol 2006; 25:135-41; PMID:16569192; http://dx.doi.org/10.1089/ dna.2006.25.135.
34. Ravasi T, Suzuki H, Pang KC, Katayama S, Furuno M, Okunishi R, et al. Experimental validation of the regulated expression of large numbers of non-coding RNAs from the mouse genome. Genome Res 2006; 16:11-9; PMID:16344565; http://dx.doi.org/10.1101/gr.4200206.
35. Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev 2009; 23:1494-504; PMID:19571179; http://dx.doi.org/10.1101/gad.1800909.
36. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464:1071-6; PMID:20393566; http://dx.doi.org/10.1038/nature08975.
37. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010; 329:689-93; PMID:20616235; http://dx.doi.org/10.1126/science.1192002.
38. Zhao J, Ohsumi TK, Kung JT, Ogawa Y, Grau DJ, Sarma K, et al. Genome-wide identification of polycomb-associated RNAs by RIP-seq. Mol Cell 2010; 40:939-53; PMID:21172659; http://dx.doi.org/10.1016/j.molcel.2010.12.011.
39. Feng J, Bi C, Clark BS, Mady R, Shah P, Kohtz JD. The Evf-2 noncoding RNA is transcribed from the Dlx-5/6 ultraconserved region and functions as a Dlx-2 transcriptional coactivator. Genes Dev 2006; 20:1470-84; PMID:16705037; http://dx.doi.org/10.1101/gad.1416106.
40. Martianov I, Ramadass A, Serra Barros A, Chow N, Akoulitchev A. Repression of the human dihydrofolate reductase gene by a non-coding interfering transcript. Nature 2007; 445:666-70; PMID:17237763; http://dx.doi.org/10.1038/ nature05519.
41. Wang X, Arai S, Song X, Reichart D, Du K, Pascual G, et al. Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature 2008; 454:126-30; PMID:18509338; http://dx.doi.org/10. 1038/nature06992.
42. Beltran M, Puig I, Peña C, García JM, Alvarez AB, Peña R, et al. A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial-mesenchymal transition. Genes Dev 2008; 22:756-69; PMID:18347095; http://dx.doi.org/10.1101/gad.455708.
43. Faghihi MA, Modarresi F, Khalil AM, Wood DE, Sahagan BG, Morgan TE, et al. Expression of a non-coding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat Med 2008; 14:723-30; PMID:18587408; http://dx.doi.org/10.1038/nm1784.
44. Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell 2010; 39:925-38; PMID:20797886; http://dx.doi.org/10.1016/j.molcel.2010.08.011.
45. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893-917; PMID:21351269; http://dx.doi.org/10.1002/ijc.25516.
46. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010; 60:277-300; PMID:20610543; http://dx.doi.org/10.3322/caac.20073.
47. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70; PMID:10647931; http://dx.doi.org/10.1016/S0092-8674(00)81683-9.
48. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013.
49. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999; 20:321-44; PMID:10368774; http://dx.doi.org/10.1210/er.20.3.321.
50. Lonard DM, O'Malley BW. Expanding functional diversity of the coactivators. Trends Biochem Sci 2005; 30:126-32; PMID:15752984; http://dx.doi.org/10.1016/j.tibs.2005.01.001.
51. Smith CL, O'Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 2004; 25:45-71; PMID:14769827; http://dx.doi.org/10.1210/er.2003-0023.
52. Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai MJ, O'Malley BW. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 1998; 279:1922-5; PMID:9506940; http://dx.doi.org/10.1126/ science.279.5358.1922.
53. Lanz RB, McKenna NJ, Onate SA, Albrecht U, Wong J, Tsai SY, et al. A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell 1999; 97:17-27; PMID:10199399; http://dx.doi.org/10.1016/ S0092-8674(00)80711-4.
54. Leygue E, Dotzlaw H, Watson PH, Murphy LC. Expression of the steroid receptor RNA activator in human breast tumors. Cancer Res 1999; 59:4190-3; PMID:10485452.
55. Chooniedass-Kothari S, Hamedani MK, Troup S, Hubé F, Leygue E. The steroid receptor RNA activator protein is expressed in breast tumor tissues. Int J Cancer 2006; 118:1054-9; PMID:16152589; http://dx.doi.org/10.1002/ijc. 21425.
56. Kawashima H, Takano H, Sugita S, Takahara Y, Sugimura K, Nakatani T. A novel steroid receptor co-activator protein (SRAP) as an alternative form of steroid receptor RNA-activator gene: expression in prostate cancer cells and enhancement of androgen receptor activity. Biochem J 2003; 369:163-71; PMID:12350225; http://dx.doi.org/10.1042/BJ20020743.
57. Hube F, Guo J, Chooniedass-Kothari S, Cooper C, Hamedani MK, Dibrov AA, et al. Alternative splicing of the first intron of the steroid receptor RNA activator (SRA) participates in the generation of coding and noncoding RNA isoforms in breast cancer cell lines. DNA Cell Biol 2006; 25:418-28; PMID:16848684; http://dx.doi.org/10.1089/dna.2006.25.418.
58. Cooper C, Guo J, Yan Y, Chooniedass-Kothari S, Hube F, Hamedani MK, et al. Increasing the relative expression of endogenous non-coding Steroid Receptor RNA Activator (SRA) in human breast cancer cells using modified oligonucleotides. Nucleic Acids Res 2009; 37:4518-31; PMID:19483093; http://dx.doi.org/10.1093/nar/gkp441.
59. Gajjar M, Candeias MM, Malbert-Colas L, Mazars A, Fujita J, Olivares-Illana V, et al. The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer Cell 2012; 21:25-35; PMID:22264786; http://dx.doi.org/10.1016/j.ccr.2011.11.016.
60. Lohrum MA, Ashcroft M, Kubbutat MH, Vousden KH. Identification of a cryptic nucleolar-localization signal in MDM2. Nat Cell Biol 2000; 2:179-81; PMID:10707090; http://dx.doi.org/10.1038/35004057.
61. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1999; 1:20-6; PMID:10559859; http://dx.doi.org/10.1038/8991.
62. Nguyen VT, Kiss T, Michels AA, Bensaude O. 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. Nature 2001; 414:322-5; PMID:11713533; http://dx.doi.org/10.1038/35104581.
63. Yang Z, Zhu Q, Luo K, Zhou Q. The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. Nature 2001; 414:317-22; PMID:11713532; http://dx.doi.org/10.1038/35104575.
64. Eilebrecht S, Brysbaert G, Wegert T, Urlaub H, Benecke BJ, Benecke A. 7SK small nuclear RNA directly affects HMGA1 function in transcription regulation. Nucleic Acids Res 2011; 39:2057-72; PMID:21087998; http://dx.doi.org/10.1093/ nar/gkq1153.
65. Chiappetta G, Avantaggiato V, Visconti R, Fedele M, Battista S, Trapasso F, et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 1996; 13:2439-46; PMID:8957086.
66. Chiappetta G, Manfioletti G, Pentimalli F, Abe N, Di Bonito M, Vento MT, et al. High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases. Int J Cancer 2001; 91:147-51; PMID:11146437; http://dx.doi.org/10.1002/1097-0215(200002)9999:9999〈::AID- IJC1033〉3.3.CO;2-M.
67. Hung T, Wang Y, Lin MF, Koegel AK, Kotake Y, Grant GD, et al. Extensive and coordinated transcription of noncoding RNAs within cell cycle promoters. Nat Genet 2011; 43:621-9; PMID:21642992; http://dx.doi.org/10.1038/ng.848.
68. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253:49-53; PMID:1905840; http://dx.doi.org/10.1126/ science.1905840.
69. Subramanya D, Grivas PD. HPV and cervical cancer: updates on an established relationship. Postgrad Med 2008; 120:7-13; PMID:19020360; http://dx.doi.org/10.3810/pgm.2008.11.1928.
70. Brooks CL, Gu W. p53 regulation by ubiquitin. FEBS Lett 2011; 585:2803-9; PMID:21624367; http://dx.doi.org/10.1016/j.febslet.2011.05.022.
71. Li L, Feng T, Lian Y, Zhang G, Garen A, Song X. Role of human noncoding RNAs in the control of tumorigenesis. Proc Natl Acad Sci USA 2009; 106:12956-61; PMID:19625619; http://dx.doi.org/10.1073/pnas.0906005106.
72. Patton JG, Porro EB, Galceran J, Tempst P, Nadal-Ginard B. Cloning and characterization of PSF, a novel pre-mRNA splicing factor. Genes Dev 1993; 7:393-406; PMID:8449401; http://dx.doi.org/10.1101/gad.7.3.393.
73. Song X, Sui A, Garen A. Binding of mouse VL30 retrotransposon RNA to PSF protein induces genes repressed by PSF: effects on steroidogenesis and oncogenesis. Proc Natl Acad Sci USA 2004; 101:621-6; PMID:14704271; http://dx.doi.org/10.1073/pnas.0307794100.
74. Song X, Sun Y, Garen A. Roles of PSF protein and VL30 RNA in reversible gene regulation. Proc Natl Acad Sci USA 2005; 102:12189-93; PMID:16079199; http://dx.doi.org/10.1073/pnas.0505179102.
75. Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, et al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene 2011; 30:1956-62; PMID:21151178; http://dx.doi.org/10.1038/onc.2010.568.
76. Yap KL, Li S, Muñoz-Cabello AM, Raguz S, Zeng L, Mujtaba S, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 2010; 38:662-74; PMID:20541999; http://dx.doi.org/10.1016/j.molcel.2010.03.021.
77. Schneider C, King RM, Philipson L. Genes specifically expressed at growth arrest of mammalian cells. Cell 1988; 54:787-93; PMID:3409319; http://dx.doi.org/10.1016/S0092-8674(88)91065-3.
78. Coccia EM, Cicala C, Charlesworth A, Ciccarelli C, Rossi GB, Philipson L, et al. Regulation and expression of a growth arrest-specific gene (gas5) during growth, differentiation and development. Mol Cell Biol 1992; 12:3514-21; PMID:1630459.
79. Muller AJ, Chatterjee S, Teresky A, Levine AJ. The gas5 gene is disrupted by a frameshift mutation within its longest open reading frame in several inbred mouse strains and maps to murine chromosome 1. Mamm Genome 1998; 9:773-4; PMID:9716666; http://dx.doi.org/10.1007/s003359900862.
80. Raho G, Barone V, Rossi D, Philipson L, Sorrentino V. The gas 5 gene shows four alternative splicing patterns without coding for a protein. Gene 2000; 256:13-7; PMID:11054530; http://dx.doi.org/10.1016/S0378-1119(00)00363-2.
81. Smith CM, Steitz JA. Classification of gas5 as a multi-small-nucleolar- RNA (snoRNA) host gene and a member of the 5′-terminal oligopyrimidine gene family reveals common features of snoRNA host genes. Mol Cell Biol 1998; 18:6897-909; PMID:9819378.
82. Kino T, Hurt DE, Ichijo T, Nader N, Chrousos GP. Noncoding RNA gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor. Sci Signal 2010; 3:8; PMID:20124551; http://dx.doi.org/10.1126/ scisignal.2000568.
83. Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F, Williams GT. GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene 2009; 28:195-208; PMID:18836484; http://dx.doi.org/10. 1038/onc.2008.373.
84. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004; 23:3151-71; PMID:15094765; http://dx.doi.org/10. 1038/sj.onc.1207542.
85. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18:1926-45; PMID:15314020; http://dx.doi.org/10.1101/gad.1212704.
86. Mourtada-Maarabouni M, Hasan AM, Farzaneh F, Williams GT. Inhibition of human T-cell proliferation by mammalian target of rapamycin (mTOR) antagonists requires noncoding RNA growth-arrest-specific transcript 5 (GAS5). Mol Pharmacol 2010; 78:19-28; PMID:20421347; http://dx.doi.org/10.1124/mol.110.064055.
87. Morrison LE, Jewell SS, Usha L, Blondin BA, Rao RD, Tabesh B, et al. Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3 and 10 on patient response to trastuzumab in metastatic breast cancer. Genes Chromosomes Cancer 2007; 46:397-405; PMID:17243161; http://dx.doi.org/10.1002/ gcc.20419.
88. Nupponen NN, Carpten JD. Prostate cancer susceptibility genes: many studies, many results, no answers. Cancer Metastasis Rev 2001; 20:155-64; PMID:12085959; http://dx.doi.org/10.1023/A:1015557308033.
89. Smedley D, Sidhar S, Birdsall S, Bennett D, Herlyn M, Cooper C, et al. Characterization of chromosome 1 abnormalities in malignant melanomas. Genes Chromosomes Cancer 2000; 28:121-5; PMID:10738310; http://dx.doi.org/10.1002/ (SICI)1098-2264(200005)28:1〈121::AID-GCC14〉3.0.CO;2-O.
90. Morris KV, Santoso S, Turner AM, Pastori C, Hawkins PG. Bidirectional transcription directs both transcriptional gene activation and suppression in human cells. PLoS Genet 2008; 4:1000258; PMID:19008947; http://dx.doi.org/10. 1371/journal.pgen.1000258.
91. Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 2005; 6:611-22; PMID:16136653; http://dx.doi.org/10.1038/nrg1656.
92. Shay JW, Wright WE. Hayflick, his limit and cellular ageing. Nat Rev Mol Cell Biol 2000; 1:72-6; PMID:11413492; http://dx.doi.org/10.1038/35036093.
93. Meyne J, Ratliff RL, Moyzis RK. Conservation of the human telomere sequence (TTA GGG)n among vertebrates. Proc Natl Acad Sci USA 1989; 86:7049-53; PMID:2780561; http://dx.doi.org/10.1073/pnas.86.18.7049.
94. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992; 11:1921-9; PMID:1582420.
95. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 1997; 3:1271-4; PMID:9359704; http://dx.doi.org/10.1038/nm1197-271.
96. Henson JD, Cao Y, Huschtscha LI, Chang AC, Au AY, Pickett HA, et al. DNA C-circles are specific and quantifiable markers of alternative-lengthening-of- telomeres activity. Nat Biotechnol 2009; 27:1181-5; PMID:19935656; http://dx.doi.org/10.1038/nbt.1587.
97. Molenaar C, Wiesmeijer K, Verwoerd NP, Khazen S, Eils R, Tanke HJ, et al. Visualizing telomere dynamics in living mammalian cells using PNA probes. EMBO J 2003; 22:6631-41; PMID:14657034; http://dx.doi.org/10.1093/emboj/cdg633.
98. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33:787-91; PMID:9282118; http://dx.doi.org/10.1016/S0959- 8049(97)00062-2.
99. Tomaska L, Nosek J, Kramara J, Griffith JD. Telomeric circles: universal players in telomere maintenance? Nat Struct Mol Biol 2009; 16:1010-5; PMID:19809492; http://dx.doi.org/10.1038/nsmb.1660.
100. Tomaska L, Nosek J, Makhov AM, Pastorakova A, Griffith JD. Extragenomic double-stranded DNA circles in yeast with linear mitochondrial genomes: potential involvement in telomere maintenance. Nucleic Acids Res 2000; 28:4479-87; PMID:11071936; http://dx.doi.org/10.1093/nar/28.22.4479.
101. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, et al. The RNA component of human telomerase. Science 1995; 269:1236-41; PMID:7544491; http://dx.doi.org/10.1126/science.7544491.
102. Andersson S, Wallin KL, Hellström AC, Morrison LE, Hjerpe A, Auer G, et al. Frequent gain of the human telomerase gene TERC at 3q26 in cervical adenocarcinomas. Br J Cancer 2006; 95:331-8; PMID:16847471; http://dx.doi.org/ 10.1038/sj.bjc.6603253.
103. Nowak T, Januszkiewicz D, Zawada M, Pernak M, Lewandowski K, Rembowska J, et al. Amplification of hTERT and hTERC genes in leukemic cells with high expression and activity of telomerase. Oncol Rep 2006; 16:301-5; PMID:16820907.
104. Phatak P, Burger AM. Telomerase and its potential for therapeutic intervention. Br J Pharmacol 2007; 152:1003-11; PMID:17603541; http://dx.doi.org/10.1038/sj.bjp.0707374.
105. Theimer CA, Feigon J. Structure and function of telomerase RNA. Curr Opin Struct Biol 2006; 16:307-18; PMID:16713250; http://dx.doi.org/10.1016/j.sbi. 2006.05.005.
106. Wyatt HD, West SC, Beattie TL. InTERTpreting telomerase structure and function. Nucleic Acids Res 2010; 38:5609-22; PMID:20460453; http://dx.doi.org/10.1093/nar/gkq370.
107. Azzalin CM, Reichenbach P, Khoriauli L, Giulotto E, Lingner J. Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends. Science 2007; 318:798-801; PMID:17916692; http://dx.doi.org/10.1126/science. 1147182.
108. Luke B, Lingner J. TERRA: telomeric repeat-containing RNA. EMBO J 2009; 28:2503-10; PMID:19629047; http://dx.doi.org/10.1038/emboj.2009.166.
109. Schoeftner S, Blasco MA. Developmentally regulated transcription of mammalian telomeres by DNA-dependent RNA polymerase II. Nat Cell Biol 2008; 10:228-36; PMID:18157120; http://dx.doi.org/10.1038/ncb1685.
110. Caslini C. Transcriptional regulation of telomeric non-coding RNA: implications on telomere biology, replicative senescence and cancer. RNA Biol 2010; 7:18-22; PMID:19901520; http://dx.doi.org/10.4161/rna.7.1.10257.
111. Deng Z, Norseen J, Wiedmer A, Riethman H, Lieberman PM. TERRA RNA binding to TRF2 facilitates heterochromatin formation and ORC recruitment at telomeres. Mol Cell 2009; 35:403-13; PMID:19716786; http://dx.doi.org/10.1016/j.molcel. 2009.06.025.
112. Redon S, Reichenbach P, Lingner J. The non-coding RNA TERRA is a natural ligand and direct inhibitor of human telomerase. Nucleic Acids Res 2010; 38:5797-806; PMID:20460456; http://dx.doi.org/10.1093/nar/gkq296.
113. Flynn RL, Centore RC, O'Sullivan RJ, Rai R, Tse A, Songyang Z, et al. TERRA and hnRNPA1 orchestrate an RPA-to-POT1 switch on telomeric single-stranded DNA. Nature 2011; 471:532-6; PMID:21399625; http://dx.doi.org/10.1038/ nature09772.
114. Ng LJ, Cropley JE, Pickett HA, Reddel RR, Suter CM. Telomerase activity is associated with an increase in DNA methylation at the proximal subtelomere and a reduction in telomeric transcription. Nucleic Acids Res 2009; 37:1152-9; PMID:19129228; http://dx.doi.org/10.1093/nar/gkn1030.
115. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3:453-8; PMID:12778135; http://dx.doi.org/10.1038/nrc1098.
116. Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 2010; 70:5649-69; PMID:20610625; http://dx.doi.org/10.1158/0008-5472.CAN-10-1040.
117. Klymkowsky MW, Savagner P. Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am J Pathol 2009; 174:1588-93; PMID:19342369; http://dx.doi.org/10.2353/ajpath.2009.080545.
118. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9:265-73; PMID:19262571; http://dx.doi.org/10.1038/nrc2620.
119. Yilmaz M, Christofori G. EMT, the cytoskeleton and cancer cell invasion. Cancer Metastasis Rev 2009; 28:15-33; PMID:19169796; http://dx.doi.org/10.1007/ s10555-008-9169-0.
120. Berx G, van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol 2009; 1:3129; PMID:20457567; http://dx.doi.org/10.1101/cshperspect.a003129.
121. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 2004; 4:118-32; PMID:14964308; http://dx.doi.org/10.1038/nrc1276.
122. Egeblad M, Rasch MG, Weaver VM. Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol 2010; 22:697-706; PMID:20822891; http://dx.doi.org/10.1016/j.ceb.2010.08.015.
123. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9:239-52; PMID:19279573; http://dx.doi.org/10.1038/nrc2618.
124. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6:392-401; PMID:16572188; http://dx.doi.org/10.1038/nrc1877.
125. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141:39-51; PMID:20371344; http://dx.doi.org/10.1016/j. cell.2010.03.014.
126. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141:52-67; PMID:20371345; http://dx.doi.org/10.1016/j.cell.2010.03.015.
127. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006; 6:764-75; PMID:16990854; http://dx.doi.org/10.1038/ nrc1949.
128. Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, et al. MALAT-1, a novel noncoding RNA and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003; 22:8031-41; PMID:12970751; http://dx.doi.org/10.1038/sj.onc.1206928.
129. Gutschner T, Baas M, Diederichs S. Noncoding RNA gene silencing through genomic integration of RNA destabilizing elements using zinc finger nucleases. Genome Res 2011; 21:1944-54; PMID:21844124; http://dx.doi.org/10.1101/gr.122358. 111.
130. Wilusz JE, Freier SM, Spector DL. 3′ end processing of a long nuclear-retained noncoding RNA yields a tRNA-like cytoplasmic RNA. Cell 2008; 135:919-32; PMID:19041754; http://dx.doi.org/10.1016/j.cell.2008.10.012.
131. Lin R, Roychowdhury-Saha M, Black C, Watt AT, Marcusson EG, Freier SM, et al. Control of RNA processing by a large non-coding RNA overexpressed in carcinomas. FEBS Lett 2011; 585:671-6; PMID:21266177; http://dx.doi.org/10.1016/ j.febslet.2011.01.030.
132. Yang L, Lin C, Liu W, Zhang J, Ohgi KA, Grinstein JD, et al. ncRNA- and Pc2 methylation-dependent gene relocation between nuclear structures mediates gene activation programs. Cell 2011; 147:773-88; PMID:22078878; http://dx.doi.org/10.1016/j.cell.2011.08.054.
133. Guo F, Li Y, Liu Y, Wang J, Li Y, Li G. Inhibition of metastasis-associated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells suppresses cell proliferation and invasion. Acta Biochim Biophys Sin (Shanghai) 2010; 42:224-9; PMID:20213048; http://dx.doi.org/10.1093/abbs/ gmq008.
134. Lin R, Maeda S, Liu C, Karin M, Edgington TS. A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene 2007; 26:851-8; PMID:16878148; http://dx.doi.org/10.1038/sj.onc. 1209846.
135. Yamada K, Kano J, Tsunoda H, Yoshikawa H, Okubo C, Ishiyama T, et al. Phenotypic characterization of endometrial stromal sarcoma of the uterus. Cancer Sci 2006; 97:106-12; PMID:16441420; http://dx.doi.org/10.1111/j.1349-7006.2006. 00147.x.
136. Tano K, Mizuno R, Okada T, Rakwal R, Shibato J, Masuo Y, et al. MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes. FEBS Lett 2010; 584:4575-80; PMID:20937273; http://dx.doi.org/10.1016/j.febslet.2010.10.008.
137. Yang Z, Zhou L, Wu LM, Lai MC, Xie HY, Zhang F, et al. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol 2011; 18:1243-50; PMID:21327457; http://dx.doi.org/10.1245/s10434-011-1581-y.
138. Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T, et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res 2011; 71:6320-6; PMID:21862635; http://dx.doi.org/10.1158/0008-5472.CAN-11-1021.
139. Niinuma T, Suzuki H, Nojima M, Nosho K, Yamamoto H, Takamaru H, et al. Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. Cancer Res 2012; 72:1126-36; PMID:22258453; http://dx.doi.org/10.1158/0008-5472.CAN-11-1803.
140. Geng YJ, Xie SL, Li Q, Ma J, Wang GY. Large intervening non-coding RNA
141. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-64; PMID:8756718; http://dx.doi.org/10.1016/S0092-8674(00)80108-7.
142. Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. Semin Cancer Biol 2009; 19:329-37; PMID:19482086; http://dx.doi.org/10.1016/j. semcancer.2009.05.003.
143. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009; 10:165-77; PMID:19234476; http://dx.doi.org/10.1038/nrm2639.
144. Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2009; 29:789-91; PMID:19164810; http://dx.doi.org/10.1161/ATVBAHA.108. 179663.
145. Kazerounian S, Yee KO, Lawler J. Thrombospondins in cancer. Cell Mol Life Sci 2008; 65:700-12; PMID:18193162; http://dx.doi.org/10.1007/s00018-007-7486- z.
146. Rossignol F, Vaché C, Clottes E. Natural antisense transcripts of hypoxia-inducible factor 1alpha are detected in different normal and tumour human tissues. Gene 2002; 299:135-40; PMID:12459261; http://dx.doi.org/10.1016/ S0378-1119(02)01049-1.
147. Thrash-Bingham CA, Tartof KD. αHIF: a natural antisense transcript overexpressed in human renal cancer and during hypoxia. J Natl Cancer Inst 1999; 91:143-51; PMID:9923855; http://dx.doi.org/10.1093/jnci/91.2.143.
148. Uchida T, Rossignol F, Matthay MA, Mounier R, Couette S, Clottes E, et al. Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression in lung epithelial cells: implication of natural antisense HIF-1alpha. J Biol Chem 2004; 279:14871-8; PMID:14744852; http://dx.doi.org/10.1074/jbc.M400461200.
149. Cayre A, Rossignol F, Clottes E, Penault-Llorca F. αHIF but not HIF-1alpha transcript is a poor prognostic marker in human breast cancer. Breast Cancer Res 2003; 5:223-30; PMID:14580258; http://dx.doi.org/10.1186/bcr652.
150. Fish JE, Matouk CC, Yeboah E, Bevan SC, Khan M, Patil K, et al. Hypoxia-inducible expression of a natural cis-antisense transcript inhibits endothelial nitric-oxide synthase. J Biol Chem 2007; 282:15652-66; PMID:17403686; http://dx.doi.org/10.1074/jbc.M608318200.
151. Robb GB, Carson AR, Tai SC, Fish JE, Singh S, Yamada T, et al. Post-transcriptional regulation of endothelial nitric-oxide synthase by an overlapping antisense mRNA transcript. J Biol Chem 2004; 279:37982-96; PMID:15234981; http://dx.doi.org/10.1074/jbc.M400271200.
152. Xia Y, Krukoff TL. Estrogen induces nitric oxide production via activation of constitutive nitric oxide synthases in human neuroblastoma cells. Endocrinology 2004; 145:4550-7; PMID:15242984; http://dx.doi.org/10.1210/en. 2004-0327.
153. Ying L, Hofseth LJ. An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer. Cancer Res 2007; 67:1407-10; PMID:17308075; http://dx.doi.org/10.1158/0008-5472.CAN-06-2149.
154. Yamada T, Carson AR, Caniggia I, Umebayashi K, Yoshimori T, Nakabayashi K, et al. Endothelial nitric-oxide synthase antisense (NOS3AS) gene encodes an autophagy-related protein (APG9-like2) highly expressed in trophoblast. J Biol Chem 2005; 280:18283-90; PMID:15755735; http://dx.doi.org/10.1074/jbc. M413957200.
155. Li K, Blum Y, Verma A, Liu Z, Pramanik K, Leigh NR, et al. A noncoding antisense RNA in tie-1 locus regulates tie-1 function in vivo. Blood 2010; 115:133-9; PMID:19880500; http://dx.doi.org/10.1182/blood-2009-09-242180.
156. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26:1324-37; PMID:17322918; http://dx.doi.org/10.1038/sj. onc.1210220.
157. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 432:307-15; PMID:15549092; http://dx.doi.org/10.1038/nature03098.
158. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132:27-42; PMID:18191218; http://dx.doi.org/10.1016/j.cell.2007.12.018.
159. Mizushima N. Autophagy: process and function. Genes Dev 2007; 21:2861-73; PMID:18006683; http://dx.doi.org/10.1101/gad.1599207.
160. White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. Clin Cancer Res 2009; 15:5308-16; PMID:19706824; http://dx.doi.org/10. 1158/1078-0432.CCR-07-5023.
161. Galluzzi L, Kroemer G. Necroptosis: a specialized pathway of programmed necrosis. Cell 2008; 135:1161-3; PMID:19109884; http://dx.doi.org/10.1016/j. cell.2008.12.004.
162. Zong WX, Thompson CB. Necrotic death as a cell fate. Genes Dev 2006; 20:1-15; PMID:16391229; http://dx.doi.org/10.1101/gad.1376506.
163. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation and cancer. Cell 2010; 140:883-99; PMID:20303878; http://dx.doi.org/10.1016/j.cell.2010.01. 025.
164. Srikantan V, Zou Z, Petrovics G, Xu L, Augustus M, Davis L, et al. PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc Natl Acad Sci USA 2000; 97:12216-21; PMID:11050243; http://dx.doi.org/10.1073/pnas. 97.22.12216.
165. Petrovics G, Zhang W, Makarem M, Street JP, Connelly R, Sun L, et al. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene 2004; 23:605-11; PMID:14724589; http://dx.doi.org/10.1038/sj. onc.1207069.
166. Tsang WP, Wong TW, Cheung AH, Co CN, Kwok TT. Induction of drug resistance and transformation in human cancer cells by the noncoding RNA CUDR. RNA 2007; 13:890-8; PMID:17416635; http://dx.doi.org/10.1261/rna.359007.
167. Khaitan D, Dinger ME, Mazar J, Crawford J, Smith MA, Mattick JS, et al. The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer Res 2011; 71:3852-62; PMID:21558391; http://dx.doi.org/10.1158/ 0008-5472.CAN-10-4460.
168. Spizzo R, Almeida MI, Colombatti A, Calin GA. Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene 2012; PMID:22266873; http://dx.doi.org/10.1038/onc.2011.621.
169. Schmitz KM, Mayer C, Postepska A, Grummt I. Interaction of noncoding RNA with the rDNA promoter mediates recruitment of DNMT3b and silencing of rRNA genes. Genes Dev 2010; 24:2264-9; PMID:20952535; http://dx.doi.org/10.1101/gad. 590910.
170. Chu C, Qu K, Zhong FL, Artandi SE, Chang HY. Genomic maps of long noncoding RNA occupancy reveal principles of RNA-chromatin interactions. Mol Cell 2011; 44:667-78; PMID:21963238; http://dx.doi.org/10.1016/j.molcel.2011.08. 027.
171. Simon MD, Wang CI, Kharchenko PV, West JA, Chapman BA, Alekseyenko AA, et al. The genomic binding sites of a noncoding RNA. Proc Natl Acad Sci USA 2011; 108:20497-502; PMID:22143764; http://dx.doi.org/10.1073/pnas.1113536108.
172. Hafner M, Landthaler M, Burger L, Khorshid M, Hausser J, Berninger P, et al. Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell 2010; 141:129-41; PMID:20371350; http://dx.doi.org/10. 1016/j.cell.2010.03.009.
173. Matouk IJ, Abbasi I, Hochberg A, Galun E, Dweik H, Akkawi M. Highly upregulated in liver cancer noncoding RNA is overexpressed in hepatic colorectal metastasis. Eur J Gastroenterol Hepatol 2009; 21:688-92; PMID:19445043; http://dx.doi.org/10.1097/MEG.0b013e328306a3a2.
174. Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, et al. Characterization of HULC, a novel gene with striking upregulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 2007; 132:330-42; PMID:17241883; http://dx.doi.org/10.1053/j.gastro.2006.08.026.
175. Chung S, Nakagawa H, Uemura M, Piao L, Ashikawa K, Hosono N, et al. Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci 2011; 102:245-52; PMID:20874843; http://dx.doi.org/ 10.1111/j.1349-7006.2010.01737.x.
176. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002; 62:2695-8; PMID:11980670.
177. Ifere GO, Ananaba GA. Prostate cancer gene expression marker 1 (PCGEM1): a patented prostate- specific non-coding gene and regulator of prostate cancer progression. Recent Pat DNA Gene Seq 2009; 3:151-63; PMID:19891595; http://dx.doi.org/10.2174/187221509789318360.
178. Durand X, Moutereau S, Xylinas E, de la Taille A. Progensa™ PCA3 test for prostate cancer. Expert Rev Mol Diagn 2011; 11:137-44; PMID:21405964; http://dx.doi.org/10.1586/erm.10.122.
179. Huang KC, Rao PH, Lau CC, Heard E, Ng SK, Brown C, et al. Relationship of XIST expression and responses of ovarian cancer to chemotherapy. Mol Cancer Ther 2002; 1:769-76; PMID:12492109.
180. Beck AK, Pass HI, Carbone M, Yang H. Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies. Future Oncol 2008; 4:341-9; PMID:18518759; http://dx.doi.org/10.2217/14796694.4.3.341.
181. Mikulski SM, Costanzi JJ, Vogelzang NJ, McCachren S, Taub RN, Chun H, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002; 20:274-81; PMID:11773179; http://dx.doi.org/10.1200/JCO.20.1.274.
182. Ardelt B, Ardelt W, Darzynkiewicz Z. Cytotoxic ribonucleases and RNA interference (RNAi). Cell Cycle 2003; 2:22-4; PMID:12695680; http://dx.doi.org/10.4161/cc.2.1.232.
183. Ardelt W, Mikulski SM, Shogen K. Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos. Homology to pancreatic ribonucleases. J Biol Chem 1991; 266:245-51; PMID:1985896.
184. Darzynkiewicz Z, Carter SP, Mikulski SM, Ardelt WJ, Shogen K. Cytostatic and cytotoxic effects of Pannon (P-30 Protein), a novel anticancer agent. Cell Tissue Kinet 1988; 21:169-82; PMID:3224365.
185. Saxena A, Saxena SK, Shogen K. Effect of Onconase on double-stranded RNA in vitro. Anticancer Res 2009; 29:1067-71; PMID:19414347.
186. Suhasini AN, Sirdeshmukh R. Transfer RNA cleavages by onconase reveal unusual cleavage sites. J Biol Chem 2006; 281:12201-9; PMID:16497678; http://dx.doi.org/10.1074/jbc.M504488200.
187. Lee I, Lee YH, Mikulski SM, Shogen K. Effect of ONCONASE ± tamoxifen on ASPC-1 human pancreatic tumors in nude mice. Adv Exp Med Biol 2003; 530:187-96; PMID:14562716; http://dx.doi.org/10.1007/978-1-4615-0075-9-18.
188. Mikulski SM, Ardelt W, Shogen K, Bernstein EH, Menduke H. Striking increase of survival of mice bearing M109 Madison carcinoma treated with a novel protein from amphibian embryos. J Natl Cancer Inst 1990; 82:151-3; PMID:2294226; http://dx.doi.org/10.1093/jnci/82.2.151-a.
189. Juan G, Ardelt B, Li X, Mikulski SM, Shogen K, Ardelt W, et al. G1 arrest of U937 cells by onconase is associated with suppression of cyclin D3 expression, induction of p16INK4A, p21WAF1/CIP1 and p27KIP and decreased pRb phosphorylation. Leukemia 1998; 12:1241-8; PMID:9697879; http://dx.doi.org/10. 1038/sj.leu.2401100.
190. Ardelt W, Ardelt B, Darzynkiewicz Z. Ribonucleases as potential modalities in anticancer therapy. Eur J Pharmacol 2009; 625:181-9; PMID:19825371; http://dx.doi.org/10.1016/j.ejphar.2009.06.067.
191. Mikulski S, Viera A, Shogen K. Invitro synergism between a novel amphibian oocytic ribonuclease (onconase(r)) and tamoxifen, lovastatin and Cisplatin, in human ovcar-3 ovarian-carcinoma cell-line. Int J Oncol 1992; 1:779-85; PMID:21584616.
192. Mikulski SM, Viera A, Ardelt W, Menduke H, Shogen K. Tamoxifen and trifluoroperazine (Stelazine) potentiate cytostatic/cytotoxic effects of P-30 protein, a novel protein possessing anti-tumor activity. Cell Tissue Kinet 1990; 23:237-46; PMID:2357721.
193. Mikulski SM, Viera A, Darzynkiewicz Z, Shogen K. Synergism between a novel amphibian oocyte ribonuclease and lovastatin in inducing cytostatic and cytotoxic effects in human lung and pancreatic carcinoma cell lines. Br J Cancer 1992; 66:304-10; PMID:1503903; http://dx.doi.org/10.1038/bjc.1992.261.
194. Amit D, Hochberg A. Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences. J Transl Med 2010; 8:134; PMID:21162716; http://dx.doi.org/10.1186/1479-5876-8-134.
195. Hasenpusch G, Pfeifer C, Aneja MK, Wagner K, Reinhardt D, Gilon M, et al. Aerosolized BC-819 inhibits primary but not secondary lung cancer growth. PLoS One 2011; 6:20760; PMID:21687669; http://dx.doi.org/10.1371/journal.pone. 0020760.
196. Mizrahi A, Czerniak A, Levy T, Amiur S, Gallula J, Matouk I, et al. Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences. J Transl Med 2009; 7:69; PMID:19656414; http://dx.doi.org/10.1186/1479-5876-7-69.
197. Sidi AA, Ohana P, Benjamin S, Shalev M, Ransom JH, Lamm D, et al. Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 overexpressing superficial bladder cancer refractory to bacillus Calmette-Guerin. J Urol 2008; 180:2379-83; PMID:18950807; http://dx.doi.org/10. 1016/j.juro.2008.08.006.
198. Smaldone MC, Davies BJ. BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential targeted therapy of cancers. Curr Opin Mol Ther 2010; 12:607-16; PMID:20886393.
199. Clemson CM, Hutchinson JN, Sara SA, Ensminger AW, Fox AH, Chess A, et al. An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. Mol Cell 2009; 33:717-26; PMID:19217333; http://dx.doi.org/10.1016/j.molcel.2009.01.026.
200. Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, et al. CREB upregulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res 2010; 38:5366-83; PMID:20423907; http://dx.doi.org/10. 1093/nar/gkq285.
201. Willingham AT, Orth AP, Batalov S, Peters EC, Wen BG, Aza-Blanc P, et al. A strategy for probing the function of noncoding RNAs finds a repressor of NFAT. Science 2005; 309:1570-3; PMID:16141075; http://dx.doi.org/10.1126/ science.1115901.
202. Zhao J, Sun BK, Erwin JA, Song JJ, Lee JT. Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome. Science 2008; 322:750-6; PMID:18974356; http://dx.doi.org/10.1126/science.1163045.
203. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 2010; 465:1033-8; PMID:20577206; http://dx.doi.org/10.1038/ nature09144.
204. Chu Y, Yue X, Younger ST, Janowski BA, Corey DR. Involvement of argonaute proteins in gene silencing and activation by RNAs complementary to a non-coding transcript at the progesterone receptor promoter. Nucleic Acids Res 2010; 38:7736-48; PMID:20675357; http://dx.doi.org/10.1093/nar/gkq648.
205. Yochum GS, Cleland R, McWeeney S, Goodman RH. An antisense transcript induced by Wnt/beta-catenin signaling decreases E2F4. J Biol Chem 2007; 282:871-8; PMID:17121828; http://dx.doi.org/10.1074/jbc.M609391200.
206. Chen W, Böcker W, Brosius J, Tiedge H. Expression of neural BC200 RNA in human tumours. J Pathol 1997; 183:345-51; PMID:9422992; http://dx.doi.org/10.1002/(SICI)1096-9896(199711)183:3〈345:: AID-PATH930〉3.0.CO;2-8.
207. Iacoangeli A, Lin Y, Morley EJ, Muslimov IA, Bianchi R, Reilly J, et al. BC200 RNA in invasive and preinvasive breast cancer. Carcinogenesis 2004; 25:2125-33; PMID:15240511; http://dx.doi.org/10.1093/carcin/bgh228.
208. Madamanchi NR, Hu ZY, Li F, Horaist C, Moon SK, Patterson C, et al. A noncoding RNA regulates human protease-activated receptor-1 gene during embryogenesis. Biochim Biophys Acta 2002; 1576:237-45; PMID:12084570.
209. Rintala-Maki ND, Sutherland LC. Identification and characterisation of a novel antisense non-coding RNA from the RBM5 gene locus. Gene 2009; 445:7-16; PMID:19559772; http://dx.doi.org/10.1016/j.gene.2009.06.009.
210. Ginger MR, Shore AN, Contreras A, Rijnkels M, Miller J, Gonzalez-Rimbau MF, et al. A noncoding RNA is a potential marker of cell fate during mammary gland development. Proc Natl Acad Sci USA 2006; 103:5781-6; PMID:16574773; http://dx.doi.org/10.1073/pnas.0600745103.